SCHEMBL30067166

SCHEMBL30067166

C[C@@H](Oc1nn(C2COC2)cc1N)C(F)(F)F

nearest known ligand 0.33

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 1/20 0.33
MAP3K12 Q12852 13/20 0.32
MAP3K13 O43283 1/20 0.32
STK16 O75716 1/20 0.32
PAK4 O96013 1/20 0.32
NTRK1 P04629 1/20 0.32
FLT3 P36888 1/20 0.32
MAP3K9 P80192 1/20 0.32
MAP3K10 Q02779 1/20 0.32
DHODH Q02127 1/20 0.31
SLC6A9 P48067 2/20 0.31
CNR2 P34972 1/20 0.31
HDAC1 Q13547 1/20 0.30
HDAC2 Q92769 1/20 0.30
EIF4E P06730 1/20 0.30
MKNK1 Q9BUB5 1/20 0.30
MKNK2 Q9HBH9 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24752314 1.00 JAK2 (0.33) JAK2MAP3K12MAP3K13STK16PAK4
SCHEMBL24752093 0.85 MAP3K12 (0.36) JAK2MAP3K12EIF4EMKNK1MKNK2
SCHEMBL30067165 0.79 SLC6A9 (0.34) SLC6A9
SCHEMBL24752603 0.79 SLC6A9 (0.34) SLC6A9
SCHEMBL26643395 0.78 LRRK2 (0.38) MAP3K12HDAC1HDAC2
SCHEMBL24752118 0.78 SLC6A9 (0.32) DHODHSLC6A9CNR2
SCHEMBL29189608 0.78 SLC6A9 (0.32) DHODHSLC6A9CNR2
SCHEMBL29189591 0.78 SLC6A9 (0.32) DHODHSLC6A9CNR2
SCHEMBL29189564 0.78 MAP3K12 (0.33) MAP3K12MAP3K13STK16PAK4NTRK1
SCHEMBL24752362 0.75 RAF1 (0.32) HDAC1HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4355748-B1 SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI SA (FR) 2026-05-13 EP disclosed
US-20240383901-A1 SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI (FR) 2024-11-21 US disclosed
EP-4355748-A1 SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI (FR) 2024-04-24 EP disclosed
WO-2022263472-A1 SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI (FR) 2022-12-22 WO disclosed
EP-4105218-A1 SUBSTITUTED PYRROLO[2,3-D] PYRIMIDINES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI (FR) 2022-12-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240383901-A1 SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION LRRK2, PARK7, SNCA JAK2 311/4885MAP3K12 559/4885MAP3K13 364/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.